Payment overview · 2025
General Payments
$279.40
16 reported records · 3 companies
Healthcare provider profile · identity verified
Emily Beaulieu, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CONWAY, NH · NPI 1538271747
Verified facts
What the public records show
CMS Open Payments records show Emily Beaulieu, ARNP received $279.40 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 89.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $250.93 | 89.8% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.26 | 6.2% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $11.21 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $279.40 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $221.75 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $161.13 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.18 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $11.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 48 |
| Omeprazole | Omeprazole | 173 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 169 | 31 |
| Gabapentin | Gabapentin | 166 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 50 |
| Ozempic | Semaglutide | 154 | 36 |
| Jardiance | Empagliflozin | 150 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 41 |
| Losartan Potassium | Losartan Potassium | 144 | 44 |
| Furosemide | Furosemide | 143 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 43 |
| Lisinopril | Lisinopril | 138 | 39 |
| Clonazepam | Clonazepam | 112 | 27 |
| Sertraline Hcl | Sertraline Hcl | 109 | 29 |
| Eliquis | Apixaban | 102 | 20 |
| Tramadol Hcl | Tramadol Hcl | 98 | 23 |
| Metformin Hcl Er | Metformin Hcl | 96 | 29 |
| Metformin Hcl | Metformin Hcl | 95 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 21 |
| Valsartan | Valsartan | 86 | 23 |
| Montelukast Sodium | Montelukast Sodium | 83 | 22 |
| Potassium Chloride | Potassium Chloride | 81 | 26 |
| Alprazolam | Alprazolam | 80 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 24 |
| Prednisone | Prednisone | 72 | 29 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 69 | 27 |
| Pregabalin | Pregabalin | 65 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 17 |
| Simvastatin | Simvastatin | 62 | 17 |
| Lorazepam | Lorazepam | 60 | 15 |
| Bupropion Xl | Bupropion Hcl | 59 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 55 | 12 |
| Glimepiride | Glimepiride | 55 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 16 |
| Diazepam | Diazepam | 52 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 16 |
| Allopurinol | Allopurinol | 51 | 16 |
| Baclofen | Baclofen | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Atenolol | Atenolol | 46 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 22 |
| Famotidine | Famotidine | 45 | 16 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Novolog Flexpen | Insulin Aspart | 44 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | 11 |
| Morphine Sulfate | Morphine Sulfate | 35 | suppressed |
| Nystatin | Nystatin | 34 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Jantoven | Warfarin Sodium | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | 12 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 16 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Ubrelvy | Ubrogepant | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Caplyta | Lumateperone Tosylate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $279.40 · 16 records | ABBVIE INC. | NEXPLANON, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error